FDA-Approved Anti-HIV Medications
Part of HIV and Its Treatment
Antiretroviral therapy (ART) is the recommended treatment for HIV infection. ART involves taking a combination of anti-HIV medications (a regimen) daily. A regimen contains three or more anti-HIV medications from at least two different drug classes. Anti-HIV medications prevent HIV from multiplying in the body, which helps people infected with HIV live longer, healthier lives. ART may reduce the risk of transmission of HIV but anti-HIV medications can't cure HIV/AIDS.
The following table lists anti-HIV medications approved by the U.S. Food and Drug Administration (FDA) for treatment of HIV in the United States. The medications are presented by drug class and identified by generic name/acronym and brand name.
|Drug Class||Generic Name (Acronym)||Brand Name||Manufacturer||FDA Approval Date|
|Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)|
|NNRTIs bind to and alter reverse transcriptase, an enzyme HIV needs to make copies of itself.
||Delavirdine (DLV)||Rescriptor||Pfizer||April 4, 1997|
|Efavirenz (EFV)||Sustiva||Bristol-Myers Squibb||Sept. 17, 1998|
|Etravirine (ETR)||Intelence||Tibotec||Jan. 18, 2008|
|Nevirapine (NVP)||Viramune||Boehringer Ingelheim||June 21, 1996|
|Rilpivirine (RPV)||Edurant||Tibotec Therapeutics||May 20, 2011|
|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|
|NRTIs block reverse transcriptase, an enzyme HIV needs to make copies of itself.
||Abacavir (ABC)||Ziagen||GlaxoSmithKline||Dec. 17, 1998|
Videx EC (enteric-coated)
|Oct. 9, 1991|
Oct. 31, 2000
|Emtricitabine (FTC)||Emtriva, Coviracil||Gilead Sciences||July 2, 2003|
|Lamivudine (3TC)||Epivir||GlaxoSmithKline||Nov. 17, 1995|
|Stavudine (d4T)||Zerit||Bristol-Myers Squibb||June 24, 1994|
|Tenofovir DF (TDF)||Viread||Gilead Sciences||Oct. 26, 2001|
|Zidovudine (ZDV, AZT)||Retrovir||GlaxoSmithKline||March 19, 1987|
|Protease Inhibitors (PIs)|
|PIs block HIV protease, an enzyme HIV needs to make copies of itself.
|Atazanavir (ATV)||Reyataz||Bristol-Myers Squibb||June 20, 2003|
|Darunavir (DRV)||Prezista||Tibotec||June 23, 2006|
|Fosamprenavir (FPV)||Lexiva||GlaxoSmithKline, Vertex Pharmaceuticals||Oct. 20, 2003|
|Indinavir (IDV)||Crixivan||Merck||March 13, 1996|
|Nelfinavir (NFV)||Viracept||Agouron Pharmaceuticals||March 14, 1997|
|Ritonavir (RTV)||Norvir||Abbott Laboratories||March 1, 1996|
|Saquinavir (SQV)||Invirase||Hoffmann-La Roche||Dec. 6, 1995|
|Tipranavir (TPV)||Aptivus||Boehringer Ingelheim||June 22, 2005|
|Fusion inhibitors block HIV from entering the CD4 cells of the immune system.
||Enfuvirtide (T-20)||Fuzeon||Hoffmann-La Roche, Trimeris||March 13, 2003|
|CCR5 entry inhibitors block CCR5, a protein on the CD4 cells that HIV needs to enter the cells.||Maraviroc (MVC)||Selzentry||Pfizer||Aug. 6, 2007|
|Integrase inhibitors block HIV integrase, an enzyme HIV needs to make copies of itself.
||Raltegravir (RAL)||Isentress||Merck||Oct. 12, 2007|
|Fixed-dose combination tablets contain two or more anti-HIV medications from one or more drug classes.
||Abacavir, Lamivudine||Epzicom||GlaxoSmithKline||Aug. 2, 2004|
|Abacavir, Lamivudine, Zidovudine||Trizivir||GlaxoSmithKline||Nov. 14, 2000|
|Efavirenz, Emtricitabine, Tenofovir DF||Atripla||Bristol-Myers Squibb, Gilead Sciences||July 12, 2006|
|Emtricitabine, Rilpivirine, Tenofovir DF||Complera||Gilead Sciences||Aug. 10, 2011|
|Emtricitabine, Tenofovir DF||Truvada||Gilead Sciences||Aug. 2, 2004|
|Lamivudine, Zidovudine||Combivir||GlaxoSmithKline||Sept. 27, 1997|
|Lopinavir, Ritonavir||Kaletra||Abbott Laboratories||Sept. 15, 2000|
This information is based on the U.S. Department of Health and Human Services' Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.
This article was provided by AIDSinfo
. Visit the AIDSinfo website to find out more about their activities and publications.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy